Litigation Details for Galderma Laboratories, L.P. v. Sun Pharmaceutical Industries Limited (D. Del. 2016)

Galderma Laboratories, L.P. v. Sun Pharmaceutical Industries Limited (D. Del. 2016)

Docket		Date Filed	2016-10-27
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	Defendant	Referred To
Patents	7,211,267; 7,232,572; 7,749,532; 8,206,740; 8,394,405; 8,394,406; 8,470,364; 8,603,506; 8,709,478; 9,241,946
Link to Docket	External link to docket

Details for Galderma Laboratories, L.P. v. Sun Pharmaceutical Industries Limited (D. Del. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-10-27	78		families of patents: the Ashley patents, U.S. Patent Nos. 7,211,267 (the "'267 patent");…#39;946 patent") (collectively, the "Ashley patents"), and the Chang patents, U.S. …. Patent Nos. 7,749,532 (the "'532 patent"); 8,206,740 (the "'740 patent")…#39;267 patent, claims 1 and 20 of the '572 patent, claims 1 and 8 of the '506 patent, and claims…#39;740 patent; claims 2 and 19 of the '405 patent; and claims 2 and 19 of the '406 patent.	External link to document

Galderma Laboratories v. Sun Pharmaceutical: Soolantra Patent Litigation Summary

Last updated: August 2, 2026

Galderma Laboratories, L.P. v. Sun Pharmaceutical Industries Limited, No. 1:16-cv-01003-LPS, was a Hatch-Waxman patent case in the U.S. District Court for the District of Delaware. Galderma sued Sun after Sun submitted an abbreviated new drug application seeking approval for a generic version of Soolantra, Galderma's ivermectin 1% topical cream for rosacea.

The case was resolved without a publicly reported merits decision. The docket reflects a negotiated disposition rather than a trial judgment invalidating or enforcing the asserted patents. The principal commercial issue was whether Sun could launch generic ivermectin cream before expiration of Galderma's Orange Book-listed patents.

What drug and ANDA were at issue in Galderma v. Sun?

The dispute concerned Soolantra cream, 1%, whose active ingredient is ivermectin. Galderma markets Soolantra for the topical treatment of inflammatory lesions of rosacea in adult patients.

Item	Case information
Court	U.S. District Court for the District of Delaware
Case number	1:16-cv-01003-LPS
Judge	Leonard P. Stark
Plaintiff	Galderma Laboratories, L.P.
Defendant	Sun Pharmaceutical Industries Limited
Product	Generic ivermectin cream, 1%
Reference product	Soolantra cream, 1%
Regulatory pathway	ANDA under the Hatch-Waxman Act
Trigger for suit	Sun's Paragraph IV certification
Disposition	Resolved without a reported merits judgment

Soolantra received FDA approval in December 2014. The product is a topical, non-steroidal rosacea treatment. Its commercial value rests on both the ivermectin active ingredient and the formulation that delivers ivermectin in a cosmetically acceptable cream.

What patents protected Soolantra in the Sun litigation?

Galderma's Soolantra patent estate included patents directed to ivermectin topical formulations and their use in treating rosacea. Publicly identified Soolantra patent rights included the following patents:

Patent	General subject matter	Relevance
U.S. Patent No. 9,192,644	Ivermectin topical compositions and treatment	Core formulation and use protection
U.S. Patent No. 9,205,063	Ivermectin pharmaceutical composition	Formulation-related protection
U.S. Patent No. 9,241,923	Ivermectin compositions and dermatological treatment	Additional formulation or method protection

The asserted claims were directed primarily to the finished topical formulation and its use, rather than to ivermectin as a compound. Ivermectin itself was an established active pharmaceutical ingredient. The strategic patent question was whether Galderma could prevent substitution with a cream containing the same active ingredient but a different excipient system, manufacturing process, or dosing instruction.

Patent coverage for a topical drug can be more difficult to enforce than compound protection. A generic applicant can avoid literal infringement by changing inactive ingredients, concentration ranges, particle characteristics, manufacturing steps, or labeling language. Galderma therefore had to rely on the precise scope of its formulation and method-of-use claims.

What legal claims did Galderma assert against Sun?

Galderma's case followed the standard Hatch-Waxman framework. Sun's ANDA allegedly contained a Paragraph IV certification stating that the relevant Soolantra patents were invalid, unenforceable, or not infringed.

Galderma responded with patent-infringement claims under 35 U.S.C. § 271(e)(2). The filing of the complaint triggered the statutory 30-month stay of FDA approval, subject to the statutory rules governing certification, notice, and court resolution.

The principal legal issues were:

1. Infringement of formulation claims.
   Galderma had to show that Sun's proposed product would meet every limitation of at least one asserted claim.

2. Infringement by the proposed label.
   If Sun's ANDA label instructed use for rosacea in a manner covered by a patented method claim, Galderma could pursue induced-infringement theories.

3. Obviousness.
   Sun could argue that a skilled formulator would have combined ivermectin with known cream excipients and arrived at the claimed product with a reasonable expectation of success.

4. Written description and enablement.
   Sun could challenge whether Galderma's patent specifications adequately supported the full breadth of the asserted formulation or treatment claims.

5. Patent-term and Orange Book scope.
   The parties also had a commercial interest in determining which listed patents could delay FDA approval and which claims had practical launch significance.

When did the Soolantra patents expire?

The relevant patent terms extended beyond Soolantra's five-year new chemical entity exclusivity period. Exact effective expiration dates depended on patent-term adjustment, terminal disclaimers, and any applicable pediatric exclusivity.

The principal dates were:

Milestone	Date or period
Soolantra FDA approval	December 2014
First likely Paragraph IV challenges	2016
Core Soolantra formulation patents issued	2015-2016
Expected ordinary patent expiration	Generally late 2020s
Possible pediatric exclusivity	Added only if FDA granted and applicable

Patent expiration should not be treated as the same as FDA exclusivity. Soolantra's five-year new chemical entity exclusivity protected the product from certain ANDA submissions for a limited period. The Orange Book-listed patents created a separate litigation and approval barrier.

What was the FDA and Orange Book status of Soolantra?

Soolantra was approved by the FDA as a prescription topical cream containing ivermectin 1%. The product was listed in the FDA Orange Book with patent information submitted by Galderma.

The regulatory structure was:

Regulatory protection	Effect
New drug application approval	Established Soolantra as the reference product
New chemical entity exclusivity	Restricted certain ANDA submissions during the initial exclusivity period
Orange Book patent listing	Required ANDA applicants to certify against listed patents
Paragraph IV certification	Allowed Sun to challenge patent validity or infringement
30-month stay	Delayed FDA approval after Galderma filed suit, subject to statutory exceptions

A Paragraph IV filing does not establish that a patent is invalid. It creates a justiciable dispute and permits the patent holder to sue. FDA approval timing depends on the litigation outcome, settlement terms, certification status, and any applicable exclusivity held by an earlier generic applicant.

How did the litigation affect generic entry?

The case delayed the regulatory path for Sun's proposed generic product while the litigation remained pending. A timely patent suit generally prevents FDA approval during the statutory stay unless the court enters a decision that changes the stay's effect or the parties reach a resolution under applicable Hatch-Waxman rules.

The public record does not reflect a reported trial decision finding the asserted Soolantra patents valid and infringed. It also does not reflect a reported decision holding the patents invalid. The case therefore did not create binding Delaware or Federal Circuit precedent on the merits of Galderma's Soolantra patent estate.

The practical result was contractual rather than precedential. A settlement could provide Sun with a future launch date, an authorized-generic arrangement, or other market-access terms while avoiding the cost and risk of a trial. Settlement terms in ANDA cases are not always publicly available in full.

What was the litigation outcome?

The action was resolved without a publicly reported merits opinion. The docket disposition indicates that the case ended through a negotiated resolution and dismissal rather than through a judgment after trial.

That outcome has four implications:

• Galderma did not obtain a publicly reported finding that every asserted patent would survive validity challenges.
• Sun did not obtain a publicly reported invalidity judgment.
• The litigation did not establish a Federal Circuit rule narrowing or expanding Galderma's Soolantra claims.
• Generic launch timing depended on the settlement and remaining Orange Book barriers, not only on the case caption's dismissal.

A dismissal in an ANDA case does not, by itself, disclose whether the branded company obtained a favorable launch restriction. The commercial terms must be evaluated separately from the procedural disposition.

Did Sun receive a Paragraph IV launch opportunity?

Sun's ANDA challenge created the possibility of a first-filer or later-filer generic launch, depending on the date and content of its certification and the status of other applicants. The publicly reported case record does not establish that Sun launched an approved generic ivermectin 1% cream immediately after the litigation ended.

The relevant launch scenarios were:

Scenario	Commercial effect
Settlement with delayed entry	Sun receives a permitted future launch date
Authorized generic arrangement	Sun may obtain supply or marketing rights outside ordinary ANDA competition
Litigation victory for Sun	FDA approval may proceed subject to regulatory requirements
Litigation victory for Galderma	Approval remains blocked until patent expiration or another legal event
Withdrawal or amendment of Paragraph IV	Litigation may end without immediate generic approval

The absence of a public merits judgment means that market-entry analysis must focus on the settlement, FDA approval records, subsequent ANDA activity, and any later litigation involving the same patents.

How strong was Galderma's Soolantra patent estate?

Galderma's estate had meaningful but differentiated protection.

Formulation protection

The strongest commercial value was in claims directed to the finished ivermectin cream. These claims could reach a generic product even when the active ingredient was old. Their value depended on claim breadth and whether Sun's proposed excipient system fell within the claimed ranges.

Method-of-use protection

Rosacea treatment claims could create a second barrier where the proposed generic label instructed use for the same indication. Method claims are vulnerable if the generic label omits the patented use or if physicians prescribe the product for unclaimed uses. They remain important where the FDA-approved label directly tracks the patented indication.

Manufacturing and process protection

Process patents can increase development and supply-chain risk but usually have less leverage over an ANDA unless the ANDA discloses the accused process or the finished product necessarily reflects the claimed manufacturing steps. A generic can sometimes design around a process patent while preserving the same therapeutic profile.

Geographic coverage

The litigation concerned U.S. patent rights and FDA approval. Galderma's international protection would depend on corresponding national patents, supplementary protection certificates, and local regulatory exclusivity. A U.S. settlement would not automatically resolve European, Canadian, or other jurisdictional rights.

Which companies challenged Soolantra patents?

Soolantra became a target for ANDA applicants because it had an established prescription market and a topical formulation that could be reproduced without discovering a new active compound. Publicly reported Soolantra patent litigation involved multiple generic manufacturers, including Sun and other ANDA applicants.

The competitive landscape included:

• Galderma as the branded sponsor and patent holder;
• Sun Pharmaceutical Industries as an ANDA challenger;
• Other generic dermatology companies evaluating ivermectin cream;
• Competing rosacea therapies, including metronidazole, azelaic acid, brimonidine, and low-dose doxycycline.

The commercial threat was substitution at the pharmacy level. Once an AB-rated generic becomes available, reimbursement systems and pharmacy substitution can rapidly reduce branded prescription volume, particularly for a topical product without strong prescriber loyalty.

What revenue exposure did Galderma face?

Soolantra's exposure was linked to the size of the U.S. rosacea market, payer coverage, the number of approved generic competitors, and the timing of entry. A single generic entrant can reduce net sales through price discounts and rebate pressure. Multiple entrants generally produce steeper erosion.

The principal revenue variables were:

1. The permitted Sun launch date.
2. Whether Sun entered alone or with other generic manufacturers.
3. The availability of an authorized generic.
4. The remaining duration of Orange Book protection.
5. The extent of off-label and cash-pay use.
6. Galderma's ability to shift patients to newer dermatology products.

Patent litigation protected the product only for the duration and scope of enforceable rights. It did not protect against competition from non-infringing rosacea therapies.

What litigation risks remain after the case dismissal?

The dismissal ended this action, but it did not eliminate all Soolantra-related risks. Remaining risks included:

• later ANDA challenges by other applicants;
• a new suit based on a different certification or patent;
• patent expiration or terminal-disclaimer issues;
• FDA approval of a non-infringing generic;
• settlement-reporting or antitrust scrutiny;
• competition from compounded ivermectin products;
• payer-driven substitution after generic approval.

The lack of a merits opinion also limits the precedential value of the case. Future challengers could litigate claim construction, obviousness, written description, or infringement independently.

Key Takeaways

• Galderma Laboratories v. Sun Pharmaceutical, No. 1:16-cv-01003-LPS, was a Delaware Hatch-Waxman case involving a proposed generic version of Soolantra, ivermectin 1% cream.
• Sun's Paragraph IV certification challenged Galderma's Orange Book-listed Soolantra patents.
• The asserted protection centered on ivermectin topical formulations and rosacea treatment methods.
• The case ended without a publicly reported merits judgment on validity or infringement.
• Generic launch timing depended on the settlement and remaining regulatory and patent barriers.
• The litigation had commercial significance because topical ivermectin could face rapid pharmacy substitution once an FDA-approved generic entered the market.
• The case produced no reported Federal Circuit precedent defining the validity or scope of Galderma's Soolantra patent estate.

FAQs

What was the product in Galderma Laboratories v. Sun Pharmaceutical?

The case concerned Sun's proposed generic ivermectin cream, 1%, equivalent to Galderma's Soolantra cream for rosacea.

Was the Soolantra patent estate invalidated?

No reported merits decision in the Sun case invalidated the asserted Soolantra patents. The action ended through a negotiated resolution and dismissal.

Did Sun launch generic Soolantra immediately after settlement?

The public case disposition does not establish an immediate commercial launch. Approval and launch depended on the settlement terms, FDA action, and remaining patent rights.

Is ivermectin cream protected by a compound patent?

The commercial protection at issue was principally formulation and method-of-use protection. Ivermectin itself was an established active ingredient.

Can another generic company still challenge Soolantra patents?

Yes. A later ANDA applicant can challenge remaining listed patents through its own certification and litigation, subject to patent expiration, exclusivity, claim scope, and prior settlement rights.

References

1. Galderma Laboratories, L.P. v. Sun Pharmaceutical Industries Limited, No. 1:16-cv-01003-LPS (D. Del. filed 2016).

2. U.S. Food and Drug Administration. (2014). Soolantra (ivermectin) cream, 1% prescribing information. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

4. U.S. Patent No. 9,192,644. (2015). Ivermectin compositions and methods of use. U.S. Patent and Trademark Office.

5. U.S. Patent No. 9,205,063. (2015). Pharmaceutical compositions containing ivermectin. U.S. Patent and Trademark Office.

6. U.S. Patent No. 9,241,923. (2016). Ivermectin compositions and methods for treating dermatological disorders. U.S. Patent and Trademark Office.